Zylox-Tonbridge Medical Technology Co., Ltd.
歸創通橋醫療科技股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 2190)

VOLUNTARY ANNOUNCEMENT

NATIONAL MEDICAL PRODUCTS ADMINISTRATION GRANTED MARKETING APPROVAL FOR NEUROVASCULAR EMBOLIZATION COILS IN CHINA

The board (the "**Board**") of director(s) (the "**Director(s)**") of Zylox-Tonbridge Medical Technology Co., Ltd. (the "**Company**", together with its subsidiaries, the "**Group**") is pleased to announce on September 27, 2021 that, our neurovascular embolization coils, independently developed in-house by the Company, has been granted the marketing approval by the National Medical Products Administration of the People's Republic of China (the "**NMPA**") for the treatment of Intracranial Hemorrhagic Stroke (the "**NMPA's Marketing Approval**").

Intracranial aneurysm embolization coil is a Class III and implantable medical device. Our neurovascular embolization coils are a set of flexible coils used in the endovascular coiling procedure, which is a minimally invasive technique using a catheter to reach the aneurysm in the brain, displace the coils to block the blood flowing into the aneurysm, thus reducing the risk of aneurysm rupture.

We have completed a multi-center, single-blind non-inferiority trial in China to evaluate the efficacy and safety of our neurovascular embolization coils. The procedures for the trial were completed in 11 centers and enrolled a total of 256 subjects, with Changhai Hospital, a Class III Grade A hospital specializing in neurovascular diseases, as the leading principal investigative institution. In conclusion, the comprehensive trial results demonstrated noninferiority as compared to a market-leading commercialized neurovascular embolization coil developed by an international medical device company (the comparable product).

Compared to other major coils on the market, our neurovascular embolization coil is extra soft and imposes minimal pressure to the aneurysm wall, thus reducing the risk to cause aneurysm rupture or other injury, and is also easier to detach from delivery system with our unique mechanical detachment mechanism. Compared to electrolytic detachable coils, this detachment mechanism is instant and there is no need of other special instruments to complete the detachment. We also offer more choices of different lengths and diameters for the coils, including six different kinds of 1mm diameter coil.

The grant of the NMPA's Marketing Approval is a significant advancement for the Group's product offering for Intracranial Hemorrhagic Stroke and the neurovascular product portfolio of the Group. It signifies the Group's achievements in neurovascular interventional medical device industry and also demonstrates the Group's ability to develop and reflects the Group's strong in-house research and development capabilities. As of today, the Group has obtained marketing approval from the NMPA for a total of 12 products in China and CE Mark for 8 products outside of China, which makes the Group a leading player in the neuro- and peripheral-vascular interventional medical device market in China in terms of total number of products approved.

After obtaining the NMPA's Marketing Approval, we intend to commercialize our neurovascular embolization coils in China and is considering to develop this product outside the China market. We plan to upgrade our neurovascular embolization coils to improve the multiple performance of coils, e.g. enhance their shape retention ability through improvements in material selection and processing techniques. Our neurovascular embolization coils is also going to be used in combination with the flow diverter to achieve better procedure efficiency for intracranial aneurysms.

Warning under Rule 18A.05 of the Listing Rules: There is no assurance that our neurovascular embolization coils will ultimately be marketed by the Company successfully. Shareholders of the Company and potential investors are advised to exercise caution when dealing in the shares of the Company.

By order of the Board
Zylox-Tonbridge Medical Technology Co., Ltd.
Dr. Jonathon Zhong Zhao
Chairman and Executive Director

Hong Kong, September 27, 2021

As of the date of this announcement, the Board comprises Dr. Jonathon Zhong Zhao, Mr. Yang Xie and Dr. Zheng Li as executive Directors, Mr. Stephen Hui Wang, Dr. Hai Lu and Dr. Steven Dasong Wang as non-executive Directors, and Dr. Jian Ji, Mr. Hongze Liang and Ms. Yun Qiu as independent non-executive Directors.